• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Planet (PL) Stock Cools As Revenue Jumps Yet Valuation Stays Rich

    Simply Wall St·09/05/2026 00:26:54
    Listen to the news

    Planet Labs stock slipped 1.3% to US$18.12 into the earnings print, after a tough three months that left the share price down about 44%. That cool reaction contrasts with a quarter built around a single headline: revenue of US$116.1m and a swing to adjusted earnings before interest, tax, depreciation and amortisation profit of US$13.9m.

    The market still seems fixated on Planet Labs being loss making on a net income basis and trading on a rich 17.4x price to sales multiple. The key question now is whether this quarter marks real operating traction or just a sentiment pause in a stretched growth story.

    Is Planet Labs PBC now priced for flawless 23.9% forecast revenue growth, or already stretched given ongoing losses and a P/S of 17.4x versus peers? Compare that gap directly inside our valuation analysis for Planet Labs PBC

    Q2 2027 Earnings Summary

    • Revenue (Q2 2027 vs. Q2 2026): US$116.1m vs. US$73.4m (strong year on year increase)
    • Net Loss (Q2 2027 vs. Q2 2026): US$9.4m loss vs. US$22.6m loss (loss narrowed)
    • Basic EPS (Q2 2027 vs. Q2 2026): US$0.03 loss per share vs. US$0.07 loss per share (loss per share narrowed)
    • Adjusted EBITDA (Q2 2027 vs. Q2 2026): US$13.9m profit vs. prior period adjusted EBITDA loss (moved into adjusted EBITDA profit)

    Prefer clean charts instead of another wall of raw earnings numbers and ratios? See Planet Labs PBC's full financial picture, including a clear view of its valuation, in our company report for Planet Labs PBC.

    NYSE:PL Trailing 12-Month Revenue & Expenses Breakdown as at Sep 2026
    NYSE:PL Trailing 12-Month Revenue & Expenses Breakdown as at Sep 2026

    Planet Labs Bull Case: Revenue Quality And Contract Wins

    Bulls argue that Planet Labs is shifting from selling imagery to running a recurring data and analytics platform, underpinned by sovereign contracts and higher margins. Q2 gives real evidence for that claim. Revenue of US$116.1m was powered by satellite services for governments, yet recurring annual contract value still accounted for 98% of total ACV, with net dollar retention at 109%. That mix points to a stickier, software like base rather than one off project work.

    The bullish view also leans heavily on sovereign momentum and backlog visibility. In this area, Planet Labs reported clear milestones. Defense and intelligence revenue grew strongly, backed by Swedish, German and Rwanda programs. Remaining performance obligations of about US$753m and backlog of about US$815m support the idea of multi year demand. Early AI products are still in beta, so the analytics narrative is partly unproven, but the data exhaust is clearly growing in value.

    Compare Planet Labs PBC's recurring revenue story and backlog strength with how institutional analysts are setting expectations. Reveal whether the street is leaning into this thesis or turning cautious with the consensus price target analysis for Planet Labs PBC.

    Planet Labs Bear Case: Profits, CapEx And Contract Reliance

    The cautious view on Planet Labs centres on weak profitability, heavy capital needs and dependence on a few large government customers. This quarter does not fully disprove that. Adjusted EBITDA of US$13.9m and year-to-date free cash flow of US$21m show the business can generate cash, yet guidance still points to an adjusted EBITDA loss in Q3 and CapEx of US$100m to US$115m for FY2027. That supports worries about ongoing cash intensity.

    Customer concentration also remains a live issue. Q2 revenue leaned heavily on point in time recognition from a Swedish sovereign satellite handover, while Defense and Intelligence grew much faster than Commercial or Civil Government. Backlog and remaining performance obligations grew, which helps visibility, but the reliance on sovereign satellite services contracts means any delay or cancellation could affect that pipeline. The small share price decline after earnings suggests investors have not fully relaxed about these risks.

    After a period of volatile trading, insider selling and recent shareholder dilution, it is worth asking if these headlines tell the full story. Review our risk analysis for Planet Labs PBC which shows 4 important warning signs.

    Own Your Next Investing Move

    If Planet Labs PBC's mix of recurring contracts, sovereign exposure and ongoing losses has your attention, register for free with Simply Wall St and add it to a Watchlist so you can track the share price against fair value and wait for a setup that fits your plan. Once you do act, use the Portfolio Command Center to cut through market noise and focus on the key fundamental and valuation updates that matter for your holdings. For a longer term view, tap into the wisdom of other investors through the Community and see how sentiment and theses evolve around Planet Labs PBC. By surfacing potential catalysts and risks early, you may be in a better position to move before the broader market reacts.

    Seeking Alternatives Beyond Planet Labs?

    Fresh stock ideas can move from quiet to flying under the radar quickly. Spot potential breakouts and pockets of momentum before the crowd while it matters. Act now.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.